Study details
Enrolling now
WU-CART-007 Trial
Wugen, Inc.
NCT IDNCT06514794ClinicalTrials.gov data as of Apr 2026
Phase
Phase 2
Target enrollment
125
Study length
about 3.9 years
Ages
1+
Locations
8 sites in CA, FL, MO +4
About this study
This trial is testing WU-CART-007, a new treatment for T-cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma. The goal is to see if WU-CART-007 can help patients achieve a complete response with no detectable cancer cells remaining.
Based on ClinicalTrials.gov records.
What participants do
- 1.Receive WU-CART-007
PhasePhase 2
DrugWU-CART-007
Primary goalMRD Pos Cohort - Response Rate
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low6%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Drug classes
cell therapy
Endpoints
Primary: MRD Pos Cohort - Response Rate, R/R Cohort - Composite Complete Response Rate
Body systems
Oncology